Skip to main content Skip to search Skip to main navigation

Mutual recognition of inspections under the EU-UK Trade Agreement

Questions about the EU-UK Trade and Cooperation Agreement, which will apply from January 1, 2021, were clarified by the European Commission in a 39-page Q&A on the EU-UK Trade and Cooperation Agreement on December 24, 2020. In total, it consists of 133 pairs of questions and answers.

To avoid supply delays and duplicate inspections, the EU and UK also mutually recognize inspections and GMP certificates. Recognition applies to manufacturers located within the territory of the issuing authority. Under certain conditions, a party may extend recognition to manufacturers outside the territory. 

The 1449-page trade and cooperation agreement covers the following areas:  

  • Trade in goods and services 
  • Digital trade 
  • Intellectual property 
  • Public procurement 
  • Aviation and road transport 
  • Energy 
  • Fisheries  
  • Social security coordination 
  • Law enforcement and judicial cooperation in criminal matters 
  • Thematic cooperation and participation in Union programs  

The detailed provisions on pharmaceuticals are found in Annex TBT-2, which comprises 12 articles and three annexes.   


Sources:

EUR-Lex: Trade and Cooperation Agreement between the European Union and the European Atomic Energy Community of the one Part, and the United Kingdom of Great Britain and Northern Ireland, of the other Part

EC: Questions & Answers: EU-UK Trade and Cooperation Agreement 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next